ANZCTR search results

This project aims to co-design, develop and pilot test a modified oral health assessment toolkit (M-OHAT) and referral system appropriate for aged care residents. Co-deisgn participants (preregistered study https://osf.io/2kynu) will review the existing OHAT and discuss oral health needs, drivers, and barriers to broader implementation. Utilising the data from the co-design workshops, OHAT modifications and a comprehensive training package will be developed for non-dental staff members at residential aged care facilities. The M-OHAT training and tool will be piloted for acceptability and validity with residents and staff of Australian residential aged care facilities.

This is a double-blind, placebo-controlled, First-in-Human Study study to assess the safety of ZE63-0302 ,and how this drug acts in the body in healthy volunteers. ZE63-0302 may be indicated for use in patients with Acute Myeloid Leukaemia (AML), but a trial of the drug in healthy volunteers is needed before trials in AML patients can proceed. Who is it for? You may be eligible for this study if you are aged 18 to 55 years and are in good general health without a clinically significant medical history. Participants with a prior cancer diagnosis are not eligible for inclusion in this study. Study details All healthy volunteer participants who choose to enrol in this study will be assigned by chance to receive a single or multiple doses of ZE63-0302 or placebo. All participants will have their vital signs checked (heart rate, blood pressure, temperature, etc), and will provide blood and urine samples for testing. It is hoped this research will determine the maximum dose of ZE63-0302 that can be administered safely without causing severe reactions. Once the dose of ZE63-0302 has been determined in healthy volunteers, a trial investigating the efficacy of ZE63-0302 as a treatment for patients with AML may proceed.

The current study evaluates the use and effectiveness of simulated workplaces, replicating real job tasks and experiences, to progressively rebuild one's capacity to return to work following an injury. To date, few return-to-work services in Australia adopt this approach. This study will therefore add to the current evidence-base by examining the preliminary effects of rehabilitation based on work simulation tasks. These data will be used to inform a future larger-scale, controlled trial.

The prevalence of chronic fatigue is high in Australia. There is a need for better understanding of underlying disease patho-physiology and reliable assessments of treatment effectiveness. This intervention study aims to assess the treatment effect of Electromagnetic Frequency (EMF) therapy for patients with chronic fatigue using the viral reactivation test, a combination of the cytology-based Circulating Rare Cell (CRC) blood test, and viral marker testing for dormant viruses such as Epstein Barr Virus (EBV), Cyto-megalo-virus (CMV), or Herpes Simplex Virus (HSV). Who is it for? You may be eligible for this study, if you have chronic fatigue. Study details Patients will undergo an intial EMF session of 60-90 min to assess treatment effectiveness of the chosen patient-specific frequency program. Effectiveness will be assessed by blood tests measuring the number of viral reactivated Circulating Rare Cells (CRC) before and 1 day after treatment. If successful, the patient will discuss with their health practitioner a 12 week treatment plan, which may involved twice weekly EMF sessions for 12 weeks. A follow-up CTC test at 3 and 6 months is scheduled to assess treatment effectiveness in the context of long-term clinical outcome. It is hoped, that this study will provide insight into the effectiveness of EMF therapy for viral reactivated chronic fatigue, with the aim to reduce viral reactivation and improve symptoms and quality of life.

The prevalence of cancer diagnosis is high and attributable to 30% of all deaths in Australia. There is a need for better treatment combined with reliable assessments of treatment effectiveness. This intervention study aims to assess the treatment effect of Electromagnetic Frequency (EMF) therapy for patients with cancer using the Circulating Tumour Cell (CTC) in cancer patients. Who is it for? You may be eligible for this study, if you have been diagnosed with cancer. Study details Patients will undergo an intial EMF session of 60-90 min to assess treatment effectiveness of the chosen patient-specific frequency program. Effectiveness will be assessed by blood tests measuring the number of Circulating Tumour Cells (CTC) before and 1 day after treatment. If successful, the patient will discuss with their health practitioner a 12 week treatment plan, which may involved twice weekly EMF sessions for 12 weeks. A follow-up CTC test at 3 months is scheduled to assess treatment effectiveness in the context of long-term clinical outcome. It is hoped, that this study will provide insight into the effectiveness of EMF therapy for cancer, with the aim to reduce CTC count, reduce tumour size and cancer spread, and improve symptoms and quality of life.

Through a co-design study we have designed an online Prescription Opioid Safety Toolkit to increase consumers knowledge about opioid pain medicines and safety relating to their use. This study will test if the effect of the Toolkit on opioid safety knowledge and behaviours, and the acceptability of the Toolkit prior to a planned national dissemination campaign.

The purpose of this trial is to assess the feasibility of a novel eye heating device for the treatment of meibomian gland dysfunction in adults with the condition compared to a commercially available heating eye mask. Various ocular observations and questionnaires will be used to assess the feasilbility.

This prospective randomised controlled trial, employing a split-mouth design, aims to investigate the impact of low-level laser therapy (LLLT) on root resorption in first premolars subjected to bite-raising forces. Conducted at the Department of Orthodontics at Sydney Dental Hospital, the study will recruit participants requiring extraction of all four first premolars for orthodontic treatment. One side of the mouth will receive a sham laser while the contralateral side will be treated with LLLT. Pain experiences will be evaluated using a Visual Analogue Scale, and pulp vitality will be tested throughout the 28-day study period. Post-extraction, micro-computed tomography will be utilised to measure the surface volume of resorption. This approach aims to provide quantitative insights into the effects of LLLT on root resorption and cemental repair, offering potential implications for orthodontic treatments.

This prospective randomised controlled trial, employing a split-mouth design, aims to investigate the impact of low-level laser therapy (LLLT) on the repair of root resorption in first premolars subjected to bite-raising forces. Conducted at the Department of Orthodontics at Sydney Dental Hospital, the study will recruit participants requiring extraction of all four first premolars for orthodontic treatment. One side of the mouth will receive a sham laser while the contralateral side will be treated with LLLT. Pain experiences will be evaluated using a Visual Analogue Scale, and pulp vitality will be tested throughout the laser therapy. Post-extraction, micro-computed tomography will be utilised to measure the surface volume of resorption. This approach aims to provide quantitative insights into the effects of LLLT on root resorption and cemental repair, offering potential implications for orthodontic treatments.

The aim of this study is to compare the efficacy of 200ml and 400ml bottles used in nasal saline irrigation by conducting a randomised controlled trial in post-Functional Endoscopic Sinus Surgery (FESS) patients.